BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30:657-68. [PMID: 17696578 DOI: 10.2165/00002018-200730080-00002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Raza A, Ngieng SC, Sime FB, Cabot PJ, Roberts JA, Popat A, Kumeria T, Falconer JR. Oral meropenem for superbugs: challenges and opportunities. Drug Discov Today 2021;26:551-60. [PMID: 33197621 DOI: 10.1016/j.drudis.2020.11.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Weinelt FA, Stegemann MS, Theloe A, Pfäfflin F, Achterberg S, Schmitt L, Huisinga W, Michelet R, Hennig S, Kloft C. Development of a Model-Informed Dosing Tool to Optimise Initial Antibiotic Dosing-A Translational Example for Intensive Care Units. Pharmaceutics 2021;13:2128. [PMID: 34959409 DOI: 10.3390/pharmaceutics13122128] [Reference Citation Analysis]
3 Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012;55:1495-502. [PMID: 22955430 DOI: 10.1093/cid/cis758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
4 Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014;69:2043-55. [PMID: 24744302 DOI: 10.1093/jac/dku111] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
5 Frumin J, Gallagher JC. Allergic Cross-Sensitivity Between Penicillin, Carbapenem, and Monobactam Antibiotics: What are the Chances? Ann Pharmacother 2009;43:304-15. [DOI: 10.1345/aph.1l486] [Cited by in Crossref: 64] [Cited by in F6Publishing: 17] [Article Influence: 4.9] [Reference Citation Analysis]
6 Wen Z, Fan S, Du C, Yin T, Zhou B, Peng Z, Xie Y, Zhang W, Chen Y, Xiao J, Chen X. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther 2017;42:221-7. [DOI: 10.1111/jcpt.12501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
7 Poulakou G, Giamarellou H. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens. Expert Opin Investig Drugs 2008;17:749-71. [PMID: 18447600 DOI: 10.1517/13543784.17.5.749] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yagi Y, Okazaki M, Higaki H, Nakai M, Hirata A, Miyamura M. Outcome evaluation of an intervention to improve the effective and safe use of meropenem. Int J Clin Pharm 2014;36:648-56. [DOI: 10.1007/s11096-014-9949-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ehmann L, Zoller M, Minichmayr IK, Scharf C, Huisinga W, Zander J, Kloft C. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents 2019;54:309-17. [PMID: 31229669 DOI: 10.1016/j.ijantimicag.2019.06.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
10 Roger C, Louart B. Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage? Microorganisms 2021;9:1505. [PMID: 34361942 DOI: 10.3390/microorganisms9071505] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Testero SA, Fisher JF, Mobashery S. β‐Lactam Antibiotics. Burger's Medicinal Chemistry and Drug Discovery. Wiley; 2003. pp. 257-402. [DOI: 10.1002/0471266949.bmc226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Cunha B, Hamid N, Krol V, Eisenstein L. Safety of Meropenem in Patients Reporting Penicillin Allergy: Lack of Allergic Cross Reactions. Journal of Chemotherapy 2013;20:233-7. [DOI: 10.1179/joc.2008.20.2.233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
13 Chytra I, Stepan M, Benes J, Pelnar P, Zidkova A, Bergerova T, Pradl R, Kasal E. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012;16:R113. [PMID: 22742765 DOI: 10.1186/cc11405] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 7.4] [Reference Citation Analysis]
14 Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008;47 Suppl 1:S41-51. [PMID: 18713049 DOI: 10.1086/590065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
15 Wurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, Merk HF, Mülleneisen N, Ott H, Pfützner W, Röseler S, Ruëff F, Sitter H, Sunderkötter C, Trautmann A, Treudler R, Wedi B, Worm M, Brockow K. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG). Allergo J Int 2019;28:121-51. [DOI: 10.1007/s40629-019-0100-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
16 Liu X, Zhao M, Chen Y, Bian X, Li Y, Shi J, Zhang J. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents 2016;48:559-63. [PMID: 27670371 DOI: 10.1016/j.ijantimicag.2016.07.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
17 Lee KH, Ueng YF, Wu CW, Chou YC, Ng YY, Yang WC. The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews. J Clin Pharm Ther 2015;40:240-4. [PMID: 25487647 DOI: 10.1111/jcpt.12239] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68:803-38. [PMID: 18416587 DOI: 10.2165/00003495-200868060-00006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
19 Bhattacharyya S, Darby R, Berkowitz AL. Antibiotic-induced neurotoxicity. Curr Infect Dis Rep. 2014;16:448. [PMID: 25348743 DOI: 10.1007/s11908-014-0448-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
20 Smith KP, Kirby JE. Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae. Assay Drug Dev Technol 2016;14:194-206. [PMID: 27045615 DOI: 10.1089/adt.2016.701] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
21 Lee Y, Bradley N. Overview and Insights into Carbapenem Allergy. Pharmacy (Basel) 2019;7:E110. [PMID: 31398843 DOI: 10.3390/pharmacy7030110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
22 Cunha BA, Jose A, Hage J. Ertapenem: lack of allergic reactions in hospitalised adults reporting a history of penicillin allergy. Int J Antimicrob Agents 2013;42:585-6. [PMID: 24139887 DOI: 10.1016/j.ijantimicag.2013.08.015] [Reference Citation Analysis]
23 Song X, Wu Y, Cao L, Yao D, Long M. Is Meropenem as a Monotherapy Truly Incompetent for Meropenem-Nonsusceptible Bacterial Strains? A Pharmacokinetic/Pharmacodynamic Modeling With Monte Carlo Simulation. Front Microbiol 2019;10:2777. [PMID: 31849910 DOI: 10.3389/fmicb.2019.02777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 No Family Name A, Takeda Y, Kanai M, Hatano A, Yoshimi Y, Kida M. A "Single-Use" Ceramic-Based Electrochemical Sensor Chip Using Molecularly Imprinted Carbon Paste Electrode. Sensors (Basel) 2020;20:E5847. [PMID: 33081095 DOI: 10.3390/s20205847] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Beer R, Lackner P, Pfausler B, Schmutzhard E. Nosocomial ventriculitis and meningitis in neurocritical care patients. J Neurol. 2008;255:1617-1624. [PMID: 19156484 DOI: 10.1007/s00415-008-0059-8] [Cited by in Crossref: 137] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
26 Zhanel GG, Ketter N, Rubinstein E, Friedland I, Redman R. Overview of Seizure-Inducing Potential of Doripenem: . Drug Safety 2009;32:709-16. [DOI: 10.2165/00002018-200932090-00001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
27 Terbtothakun P, Nwabor OF, Siriyong T, Voravuthikunchai SP, Chusri S. Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-Resistant Escherichia coli Harboring blaNDM-1 and blaNDM-5. Antibiotics (Basel) 2021;10:1023. [PMID: 34439073 DOI: 10.3390/antibiotics10081023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pham TNM, Le TB, Le DD, Ha TH, Nguyen NS, Pham TD, Hauser PC, Nguyen TAH, Mai TD. Determination of carbapenem antibiotics using a purpose-made capillary electrophoresis instrument with contactless conductivity detection. J Pharm Biomed Anal 2020;178:112906. [PMID: 31634756 DOI: 10.1016/j.jpba.2019.112906] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
29 Van Tuyl JS, Jones AN, Johnson PN. Meropenem-Induced Neutropenia in a Neonate. J Pediatr Pharmacol Ther 2016;21:353-7. [PMID: 27713676 DOI: 10.5863/1551-6776-21.4.353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
30 Terico AT, Gallagher JC. Beta-Lactam Hypersensitivity and Cross-Reactivity. Journal of Pharmacy Practice 2014;27:530-44. [DOI: 10.1177/0897190014546109] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
31 De Bus L, Depuydt P, Libbrecht L, Vandekerckhove L, Nollet J, Benoit D, Vogelaers D, Van Vlierberghe H. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol. 2010;6:322-326. [PMID: 20358416 DOI: 10.1007/s13181-010-0047-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
32 Garnica-Velandia S, Aristizábal-Ruiz LA, Alvarez-Moreno CA. Real-World Use of Generic Meropenem: Results of an Observational Study. Antibiotics (Basel) 2021;10:62. [PMID: 33440602 DOI: 10.3390/antibiotics10010062] [Reference Citation Analysis]
33 Mattappalil A, Mergenhagen KA. Neurotoxicity with Antimicrobials in the Elderly: A Review. Clinical Therapeutics 2014;36:1489-1511.e4. [DOI: 10.1016/j.clinthera.2014.09.020] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 6.1] [Reference Citation Analysis]
34 Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015;85:1332-41. [PMID: 26400582 DOI: 10.1212/WNL.0000000000002023] [Cited by in Crossref: 94] [Cited by in F6Publishing: 33] [Article Influence: 13.4] [Reference Citation Analysis]
35 Martin-canal G, Saavedra A, Asensi J, Suarez-zarracina T, Rodriguez-guardado A, Bustillo E, Fierer J, Carton J, Collazos J, Asensi V. Meropenem monotherapy is as effective as and safer than imipenem to treat brain abscesses. International Journal of Antimicrobial Agents 2010;35:301-4. [DOI: 10.1016/j.ijantimicag.2009.11.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
36 Wurpts G, Aberer W, Dickel H, Brehler R, Jakob T, Kreft B, Mahler V, Merk HF, Mülleneisen N, Ott H, Pfützner W, Röseler S, Ruëff F, Sitter H, Sunderkötter C, Trautmann A, Treudler R, Wedi B, Worm M, Brockow K. Guideline on diagnostic procedures for suspected hypersensitivity to beta-lactam antibiotics: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Society of Allergology (AeDA), German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Austrian Society for Allergology and Immunology (ÖGAI), and the Paul-Ehrlich Society for Chemotherapy (PEG). Allergol Select 2020;4:11-43. [PMID: 32568254 DOI: 10.5414/ALX02104E] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Alvis Miranda H, Castellar-Leones SM, Elzain MA, Moscote-Salazar LR. Brain abscess: Current management. J Neurosci Rural Pract 2013;4:S67-81. [PMID: 24174804 DOI: 10.4103/0976-3147.116472] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 6.1] [Reference Citation Analysis]
38 Venkatesh MP, Garcia-Prats JA. Management of neonatal sepsis by Gram-negative pathogens. Expert Rev Anti Infect Ther 2008;6:929-38. [PMID: 19053905 DOI: 10.1586/14787210.6.6.929] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
39 Gatti M, Raschi E, De Ponti F. Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study. BMC Pharmacol Toxicol 2019;20:65. [PMID: 31718688 DOI: 10.1186/s40360-019-0364-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kim BN, Peleg AY, Lodise TP, Lipman J, Li J, Nation R, Paterson DL. Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis. 2009;9:245-255. [PMID: 19324297 DOI: 10.1016/s1473-3099(09)70055-6] [Cited by in Crossref: 132] [Cited by in F6Publishing: 52] [Article Influence: 10.2] [Reference Citation Analysis]
41 Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, Dragoescu PO, Fedosiuk E, Horcajada JP, Murta C, Sarychev Y, Stoev V, Morgan E, Fusaro K, Griffith D, Lomovskaya O, Alexander EL, Loutit J, Dudley MN, Giamarellos-Bourboulis EJ. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018;319:788-99. [PMID: 29486041 DOI: 10.1001/jama.2018.0438] [Cited by in Crossref: 164] [Cited by in F6Publishing: 137] [Article Influence: 41.0] [Reference Citation Analysis]
42 Deshayes S, Coquerel A, Verdon R. Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review. Drug Saf 2017;40:1171-98. [PMID: 28755095 DOI: 10.1007/s40264-017-0578-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
43 Cohen KA, El-Hay T, Wyres KL, Weissbrod O, Munsamy V, Yanover C, Aharonov R, Shaham O, Conway TC, Goldschmidt Y, Bishai WR, Pym AS. Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics. EBioMedicine 2016;9:170-9. [PMID: 27333036 DOI: 10.1016/j.ebiom.2016.05.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
44 Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013;32:748-53. [PMID: 23838776 DOI: 10.1097/INF.0b013e31828be70b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
45 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-hady H. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatric Infectious Disease Journal 2017;36:358-63. [DOI: 10.1097/inf.0000000000001445] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
46 Robertson AD, Li C, Hammond DA, Dickey TA. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin‐Tazobactam or Meropenem. Pharmacotherapy 2018;38:1184-93. [DOI: 10.1002/phar.2179] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
47 Masterton RG. The new treatment paradigm and the role of carbapenems. International Journal of Antimicrobial Agents 2009;33:105.e1-8. [DOI: 10.1016/j.ijantimicag.2008.07.023] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
48 Lim CL, Lee W, Lee AL, Liew LT, Nah SC, Wan CN, Chlebicki MP, Kwa AL. Evaluation of Ertapenem use with impact assessment on extended-spectrum beta-lactamases (ESBL) production and gram-negative resistance in Singapore General Hospital (SGH). BMC Infect Dis 2013;13:523. [PMID: 24195651 DOI: 10.1186/1471-2334-13-523] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
49 Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011;31:408-23. [PMID: 21449629 DOI: 10.1592/phco.31.4.408] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
50 Nicolau DP. Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opin Pharmacother 2009;10:1213-22. [PMID: 19405794 DOI: 10.1517/14656560902900853] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]